hotspot -WSS

hotspot

author：entertainment 2025-10-01 21:12:50 - browse：3

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

entertainment

WSS

Novo Nordisk testing Wegovy against alcohol

WuXi Biologics beefs up its lobbying operation

In Spain, a hospital brews its own CAR

Why health records don't always know when patients are dead

Christmas in the PICU brings some surprising joy

SNAP should offer more nutrition education

leisure time

hotspot

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

WuXi Biologics beefs up its lobbying operation

Psychedelics group wrestles with new pharma identity

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why health care costs have stayed mostly flat since 2010

Medicare proposal to cover medical devices draws a mixed reaction

WuXi Biologics execs register to lobby as Congress comes for the company

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

SEC charges former device maker CEO with $41 million fraud

Wikipedia

WuXi Biologics execs register to lobby as Congress comes for the company

Obesity drug from Roche shows promise in early study

ALS treatment from Biogen, Ionis fails in study

STAT reporters are Pulitzer Prize finalists for investigative reporting

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Supreme Court to hear if Covid misinformation is protected speech

leisure time

entertainment

entertainment

focus